CTL Amedica’s Nitro interbody fusion cage system portfolio was cleared by the FDA, the devicemaker said May 18.
Nitro is a silicon nitride implant that is designed for greater protein absorption, increased osseointegration and better bone growth, according to a news release. The Nitro portfolio includes devices for a variety of spinal fusion procedures.
The Matisse Nitro ACIF cage system will launch later in 2023, followed by the rest of the Nitro systems.
Centinel Spine, a global medical device company, reported a 33% increase in year-over-year revenue during the first quarter of 2025. …
Aurora Spine reported $17.6 million in revenue during fiscal year 2024, an increase of more than 20% over the previous…
Globus Medical CEO Daniel Scavilla’s salary rose to $4.8 million in 2024, according to the company’s April 25 Securities and…
Comments are closed.